Intranasal administration of dauricine loaded on graphene oxide: multi-target therapy for Alzheimer's disease

Drug Delivery
2021.0

Abstract

Alzheimer's disease (AD) is a degenerative disease of the central nervous system characterized by progressive cognitive and memory-related impairment. However, current therapeutic treatments have not proved sufficiently effective, mainly due to the complicated pathogenesis of the disease. In this study, a nano-formulation of graphene oxide (GO) loaded with dauricine (Dau) was investigated in terms of the combined anti-inflammatory and anti-oxidative stress effects of Dau and the inhibition of misfolding and aggregation of the amyloid-beta (Abeta) protein by GO. Both in vivo and in vitro models were induced using Abeta(1-42), and the formulation was administered nasally in mice. The results showed that GO loaded with Dau greatly reduced oxidative stress through increasing superoxide dismutase levels and decreasing reactive oxygen species and malondialdehyde levels in vitro; it also alleviated the cognitive memory deficits and brain glial cell activation in mice with Abeta(1-42)-induced AD. This proved that GO loaded with Dau could protect against Abeta(1-42)-induced oxidative damage and apoptosis in both in vitro and in vivo AD models; therefore, GO loaded with Dau has the potential to be an effective and agent for the rapid treatment of AD.

Knowledge Graph

Similar Paper

Intranasal administration of dauricine loaded on graphene oxide: multi-target therapy for Alzheimer's disease
Drug Delivery 2021.0
Dauricine Attenuates Spatial Memory Impairment and Alzheimer-Like Pathologies by Enhancing Mitochondrial Function in a Mouse Model of Alzheimer's Disease
Frontiers in Cell and Developmental Biology 2021.0
Dauricine alleviates cognitive impairment in Alzheimer's disease mice induced by D-galactose and AlCl3 via the Ca2+/CaM pathway
Toxicology and Applied Pharmacology 2023.0
Design, synthesis and evaluation of 2-arylethenyl- N -methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment
European Journal of Medicinal Chemistry 2017.0
DL -3- n -butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid- β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer’s therapy
Bioorganic & Medicinal Chemistry Letters 2017.0
A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine-induced mouse model
European Journal of Medicinal Chemistry 2020.0
Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease
European Journal of Medicinal Chemistry 2022.0
Novel 8-hydroxyquinoline derivatives targeting β-amyloid aggregation, metal chelation and oxidative stress against Alzheimer’s disease
Bioorganic & Medicinal Chemistry 2018.0
Design, synthesis and evaluation of diosgenin carbamate derivatives as multitarget anti-Alzheimer’s disease agents
European Journal of Medicinal Chemistry 2020.0
Design, synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease
European Journal of Medicinal Chemistry 2014.0